MuscleView 2.0

K251682

Springbok, Inc. (dba Springbok Analytics) · cleared 2025-09-09 · product code LNH · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.6)
MuscleView 2.0 is a software-only medical device which performs automatic segmentation of musculoskeletal structures.
Algorithmlocked artificial intelligence/machine learning (AI/ML) algorithm
source quote (p.6)
The software utilizes a locked artificial intelligence/machine learning (AI/ML) algorithm to identify and segment anatomical structures for quantitative analysis.
Adaptive (vs locked)No
source quote (p.6)
The software utilizes a locked artificial intelligence/machine learning (AI/ML) algorithm to identify and segment anatomical structures for quantitative analysis. The model behavior is locked and deterministic.
PCCPYes
source quote (p.1)
FDA's substantial equivalence determination also included the review and clearance of your Predetermined Change Control Plan (PCCP). The submission includes a Predetermined Change Control Plan which details the procedure for retraining AI/ML algorithms or adding data to the Virtual Control Groups in order to improve performance without negatively impacting the safety or efficacy of the device. A Predetermined Change Control Plan (PCCP) has been developed in accordance with the FDA Guidance "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions" (issued December 4, 2024). Modifications to the MuscleView AI/ML models will be made in accordance with the PCCP summarized below:
Cybersecurity addressedYes
source quote (p.9)
MuscleView 2.0 has been tested in alignment with the FDA's guidance on software functions ("Content of Premarket Submissions for Device Software Functions”, June 14, 2023) and cybersecurity ("Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions”, September 27, 2023). It has successfully met the predetermined acceptance criteria for the following tests: ... Cybersecurity Testing

Validation studies (1)

Retrospective clinical

n=319 patients · 19 site(s)

endpoints: dice similarity coefficient (DSC); volume difference (VDt)

Reported performance (1 observation)

diceas written: “Dice Similarity Coefficient (DSC)stated without valueCI 0.962 -0.965
source quote (p.11)
Table 1: The 95% confidence intervale for the ROIs in Al settings 1-3 for the DICE (DSC) metric.

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

100
recalls in product code, 24mo
510
MAUDE reports in code, 12mo
+5%
vs code's own 3-yr baseline
2
drift signals on this device
  • recall_reason_pattern

    Software/algorithm-related recall in product code LNH (Philips North America, initiated 2026-04-14): "The potential for stiffness value errors when a specific range of image reconstruction parameters is used in combination with Resoundant's algorithm, leading to the reconstruction " Recalling firm is another firm in the same product code.

    first seen 2026-07-08 · recall res_event_number:98779

  • recall_reason_pattern

    Software/algorithm-related recall in product code LNH (Philips North America, initiated 2025-12-03): "The potential for stiffness value errors when viewing exported MR Elastography (MRE) stiffness maps to viewer Picture Archiving and Communication System (PACS)." Recalling firm is another firm in the same product code.

    first seen 2026-07-08 · recall res_event_number:98111

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K251682